With SMEs gaining wider recognition as the powerhouse of research and innovation in Europe, regulatory agencies are urging companies to engage with regulators early in the drug-development process.

Genzyme plans to appeal FDA?s decision that the multiple-sclerosis treatment is not ready for approval.

Abrams Royal Pharmacy is recalling all unexpired lots of sterile products dispensed in the US.

Baxter International recalls dextrose injection and four sodium chloride injections.

Supernus Pharmaceuticals receives FDA approval of Orenitram for the treatment of pulmonary arterial hypertension.

This month, healthcare leaders from six of the world's top 20 pharmaceutical companies met together in collaboration with the Oliver Wyman Health Innovation Center to explore the industry's changing role in today's value-basaed healthcare structure.

Pall Corporation, a solutions provider in filtration, separation and purification, has signed a definitive agreement with ATMI to acquire ATMI's LifeSciences business unit for $185 million.

ProBioGen signs agreement with Emergent BioSolutions for access to ProBioGen's avian AGE1.CR cell line.

Leidos Holdings awards Pfenex a subcontract in support of the development of an anthrax vaccine.

Bind Therapeutics amends its development and commercialization collaboration agreement with Amgen.

A collaborative pharmaceutical project to develop paediatric formulations using smart design and predictive science has received the go ahead after securing a ?660,000 grant from UK-based Technology Strategy Board.

Everett Laboratories acquires Quinnova Pharmaceuticals, a specialty pharmaceutical company.

Merck and GlaxoSmithKline begin clinical trial of pazopanib for the treatment of advanced renal-cell carcinoma.

FDA completes an inspection of Cambrex's API manufacturing facility in Charles City, Iowa.

Siemens enters agreement with Pfizer to commercialize diagnostic tests for therapeutic products across Pfizer's pipeline.

Metrics appoints a new vice-president to manage and expand its fee-for-service operations.

CMC Biologics and OnoSynergy form an agreement from cell-line development.

Bristol-Myers Squibb agrees to sell global diabetes business to AstraZeneca for $2.7 billion upfront plus an addition $1.4 billion in potential regulatory- and sales-based milestone payments.

Pfizer appoints management changes to take effect in 2014.

Merck Serono, the biopharmaceutical division of Merck, has entered into an agreement on cancer drug development with the Spanish National Cancer Research Centre (CNIO) in Madrid.

AstraZeneca issues a statement regarding the launch of esomeprazole strontium in the United States.

FDA and EMA launch initiative to share bioequivalence inspection information.

Biogen and Samsung Bioepis, a joint venture between Samsung Biologics and Biogen Idec, advance plans for anti-TNF biosimilar product candidates.

Bridgepoint Development Capital acquires Quotient for an undisclosed sum.

Pfizer settles its litigation against Teva Pharmaceuticals regarding Pfizer's patent covering the use of Viagra.

Accelrys aquires Ireland-based Qumas, a provider of cloud-based and on-premises enterprise compliance software.

Merck's new facility for aseptic production in Reinbek, Germany is scheduled to be completed in 2016.

AstraZeneca's MedImmune will collaborate with Johns Hopkins University in both biologics and small-molecule projects.